checkAd

Onxeo to Present New Preclinical Data at AACR 2021

Nachrichtenquelle: globenewswire
08.04.2021, 18:41  |  107   |   |   

  • Confirming the effect of AsiDNA on resistance to KRAS inhibitors
  • Introducing OX400, a new generation of PARP interfering cancer drug candidates

PARIS, April 08, 2021 (GLOBE NEWSWIRE) -- Onxeo S.A. (Euronext Growth Paris: ALONX, First North Copenhagen: ONXEO), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage response (DDR), today announced the presentation of preclinical data confirming the differentiated antitumoral properties of the drug candidates generated by platON, its patent-protected platform of decoy-agonists of the DNA Damage Response, in e-poster sessions during the American Association for Cancer Research (AACR 2021) virtual annual meeting on April 10, 2021.

The first e-poster supports the ability of AsiDNA, the Company’s first-in-class DNA Damage Response (DDR) inhibitor, to prevent resistance to KRAS inhibitors (KRASi) emerging from drug-tolerant persister cells (DTC). Novel therapies targeting the inhibition of KRAS, an oncogenic protein present in a third of cancers, have shown very promising clinical results especially in non-small cell lung cancer. However, acquired resistance hinders their efficacy. Combining AsiDNA to KRASi could be an additional development opportunity for AsiDNA, in the context of its use to prevent acquired resistance to targeted therapies.

The second e-poster describes the mechanism of action of the molecules of the new OX400 family, specifically designed to interfere with PARP signaling and display immunomodulatory properties and metabolic effects.

Judith Greciet, Chief Executive Officer of Onxeo, commented: “Pharmaco-tolerant cells are a well-established cause of resistance to TKIs, and, as we already demonstrated last year, to PARP inhibitors. We have generated new data demonstrating that these cells are also involved in resistance to KRAS inhibitors and confirmed the efficacy of AsiDNA on these cells thus preventing or even reversing tumor regrowth. These results open the door for another potential combination with these innovative compounds which show high efficiency but struggle with resistance issues. In parallel, we continue to optimize the efficacy profile of the next candidates from the OX400 family, while keeping the established benefits shared by all our platON-sourced compounds in terms of safety and absence of resistance. Our new results confirm that, by trapping and exhausting specifically PARP, OX400 compounds have the potential to modulate the immune response and wear out the tumor cell metabolism. We will continue to explore these original properties.”

Seite 1 von 4


Onxeo Aktie jetzt über den Testsieger (Finanztest 11/2020) handeln, ab 0 € auf Smartbroker.de

Diesen Artikel teilen
Wertpapier



0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Disclaimer

Onxeo to Present New Preclinical Data at AACR 2021 Confirming the effect of AsiDNA on resistance to KRAS inhibitorsIntroducing OX400, a new generation of PARP interfering cancer drug candidates PARIS, April 08, 2021 (GLOBE NEWSWIRE) - Onxeo S.A. (Euronext Growth Paris: ALONX, First North …

Nachrichten des Autors

Titel
Titel
Titel
Titel